Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kainos Medicine Inc.

kainosmedicine.com

Latest From Kainos Medicine Inc.

Syntekabio Aiming To Be Pharma Companion In AI-Driven Drug Development

Syntekabio is at the forefront of artificial intelligence-driven new drug development in South Korea. Its CEO Tyson Kim talks to Scrip how the genome big data and AI platform company is helping the pharma industry to develop new drugs more efficiently and rapidly.

Artificial Intelligence South Korea

Kainos HIV Candidate Leaps Ahead In China Under Priority Review

Kainos Medicine's HIV drug candidate KM-023 is set to move directly into a Phase III program in China through local licensee Jiangsu Aidea, benefiting from the country's fast-track review system and accelerating the development of the drug, which Kainos sees as bringing multiple possible benefits over existing therapies. 

South Korea China

Tech Transfer Roundup: UCSD Sees Many Benefits From Entrepreneurs In Residence Program

Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.

Deals Research & Development

Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar

Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.

Asia Pacific Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dental & Oral Products
  • Immune Disorders
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Kainos Medicine Inc.
  • Senior Management
  • M.C. Kang, PhD, CEO
    Brian Bray, PhD, SVP, Dev.
  • Contact Info
  • Kainos Medicine Inc.
    Phone: (82) 2 567 7401
    6F Platinum Bldg., 889-51 Daechi-dong
    Gangnam-gu
    Seoul, 135-839
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register